In Vivo Localization of Fas-Associated Death Domain Protein in the Nucleus and Cytoplasm of Normal Thyroid and Liver Cells

FADD (Fas-associated death domain) is the main death receptor adaptor molecule that transmits apoptotic signal. Recently, FADD protein was shown to be expressed both in the cytoplasm and nucleus of in vitro cell lines. In contrast to the cytoplasmic FADD, the nuclear FADD was shown to protect cells from apoptosis. However, in vivo subcellular localization of FADD was still unknown. Here, we demonstrated that FADD protein was expressed in both cytoplasmic and nuclear compartment in ex vivo thyroid cells demonstrating that nuclear sublocalization of FADD protein was a relevant phenomenon occurring in vivo. Moreover, we showed that in the nucleus of untransformed thyroid cells FADD localized mainly on euchromatin. We confirmed the nuclear localization of FADD in ex vivo liver and showed that in this organ FADD and MBD4 interact together. These results demonstrate that FADD is physiologically expressed in the nucleus of cells in at least two mouse organs. This particular localization opens new possible role of FADD in vivo either asan inhibitor of cell death, or as a transcription factor, or as a molecular link between apoptosis and genome surveillance

Targeting CD226/DNAX accessory molecule-1 (DNAM-1) in collagen-induced arthritis mouse models

International audienceBackground: Genetic studies have pointed out that CD226 variants, encoding DNAM-1, could be associated with susceptibility to rheumatoid arthritis. Therefore, we aimed to determine the influence of DNAM-1 on the development of arthritis using the collagen-induced arthritis (CIA) mouse model. Methods: CIA was induced in mice on a DBA/1 background, treated in parallel with a DNAM-1 neutralizing monoclonal antibody, a control IgG and PBS, respectively. CIA was also induced in mice deficient for DNAM-1(dnam1−/−) and control dnam-1+/+ mice on a C57/BL6 background. Mice were monitored for clinical and ultrasound signs of arthritis. Histological analysis was performed to search for inflammatory infiltrates and erosions. The Mann–Whitney U test for non-related samples was used for statistical analysis. Results: There was a non-significant trend for a less arthritic phenotype in mice receiving anti-DNAM-1 mAb at both clinical, ultrasound and histological assessments. But, we did not observe any difference between dnam1+/+ and dnam1−/− mice for incidence nor severity of clinical arthritis. Histological analysis revealed inflammatory scores similar in both groups, without evidence of erosion. Collagen antibodies levels were similar in all mice, confirming immunization with collagen. Conclusion: Despite some clues suggesting a role of DNAM-1 in arthritis, these complementary approaches demonstrate no contribution of CD226/DNAM-1 in the arthritic phenotype. These results contrast with previous studies showing a role in vivo of DNAM-1 in some autoimmune disorders

Insights into spatial configuration of a galactosylated epitope required to trigger arthritogenic T-cell receptors specific for the sugar moiety

The immunodominant epitope of bovine type II collagen (CII256–270) in Aq mice carries a hydroxylysine-264 linked galactose (Gal-Hyl264), the recognition of which is central to the development of collagen-induced arthritis. This study explores the molecular interactions involved in the engagement of T-cell receptors (TCRs) with such epitopes. Responses of three anti-CII T-cell hybridomas and clone A9.2 (all sharing close TCR sequences) to a panel of CII256–270 analogues incorporating Gal-Hyl264 with a modified side chain were determined. Recognition of naturally occurring CII256–270 peptides by either group of T cells depended strictly upon the presence of the carbohydrate and, more precisely, its intact HO-4 group. Modifications of primary amino group on the hydroxylysine side chain eliminated T-cell reactivity, notwithstanding the presence of the galactosyl moiety. Moderate stereochemical changes, such as altered sugar orientation and methylation at the galactose anchor position, were still permissive. Conversely, robust transformations affecting the relative positions of the key elements were detrimental to TCR recognition. To conclude, these data provide strong new experimental evidence that integrity of both galactose HO-4 and hydroxylysine side chain primary amino groups are mandatory for activation of anti-Gal-Hyl264 TCRs. They also indicate that there is a certain degree of TCR plasticity in peptide-TCR interactions

No evidence for XMRV association in pediatric idiopathic diseases in France

Retroviruses have been linked to a variety of diseases such as neoplastic and immunodeficiency disorders and neurologic and respiratory diseases. Recently, a novel infectious human retrovirus, the xenotropic murine leukemia virus-related virus (XMRV), has been identified in cohorts of patients with either a familial type of prostate cancer or chronic fatigue syndrome. The apparent unrelatedness of these diseases raised the question of the potential involvement of XMRV in other diseases

Early and long-standing rheumatoid arthritis: distinct molecular signatures identified by gene-expression profiling in synovia

International audienc

Critical role of the adhesion receptor DNAX accessory molecule-1 (DNAM-1) in the development of inflammation-driven dermal fibrosis in a mouse model of systemic sclerosis

Objective: To investigate the contribution of the adhesion receptor DNAX accessory molecule-1 (DNAM-1) in the development of dermal fibrosis on gene inactivation and targeted molecular strategies. Methods: Human skin expression of DNAM-1 was determined by immunohistochemistry. Mice deficient for DNAM-1 (dnam1−/−) and wild-type controls (dnam1+/+) were injected with bleomycin or NaCl. Infiltrating leucocytes, T cells, B cells and monocytes were quantified and inflammatory cytokines were measured in lesional skin of dnam1−/− and dnam1+/+ mice. The anti-fibrotic potential of a DNAM-1 neutralising monoclonal antibody (mAb) was evaluated in the mouse model of bleomycin-induced dermal fibrosis. Results: Overexpression of DNAM-1 was detected in the skin of patients with SSc (systemic sclerosis). Dnam1−/− mice were protected from bleomycin-induced dermal fibrosis with reduction of dermal thickening (75±5%, p=0.03), hydroxyproline content (46±8%, p=0.04) and myofibroblast counts (39±5%, p=0.01). Moreover, the number of T cells was significantly decreased in lesional skin of dnam1−/− mice (69±15%, p=0.0007). Dnam1−/− mice also displayed decreased levels of TNF-α and IL-6 in lesional skin. Consistent with the gene inactivation strategy, treatment of mice with DNAM-1 neutralising mAb prevented dermal fibrosis induced by bleomycin with reduction of dermal thickness (64±6%, p=0.002), hydroxyproline content (61±8%, p=0.004) and myofibroblast counts (83±12%, p=0.002). Conclusions: An inactivation gene strategy showed that DNAM-1 exerts profibrotic effects by controlling T cell activation and cytokine release. A molecular targeted strategy confirmed that DNAM-1 neutralising mAb has potent antifibrotic properties, supporting the hypothesis that inhibition of DNAM-1 might be a promising new approach for the treatment of SSc and potentially other related fibrotic diseases

Major histocompatibility complex associations of ankylosing spondylitis are complex and involve further epistasis with ERAP1

Ankylosing spondylitis (AS) is a common, highly heritable, inflammatory arthritis for which HLA-B*27 is the major genetic risk factor, although its role in the aetiology of AS remains elusive. To better understand the genetic basis of the MHC susceptibility loci, we genotyped 7,264 MHC SNPs in 22,647 AS cases and controls of European descent. We impute SNPs, classical HLA alleles and amino-acid residues within HLA proteins, and tested these for association to AS status. Here we show that in addition to effects due to HLA-B*27 alleles, several other HLA-B alleles also affect susceptibility. After controlling for the associated haplotypes in HLA-B, we observe independent associations with variants in the HLA-A, HLA-DPB1 and HLA-DRB1 loci. We also demonstrate that the ERAP1 SNP rs30187 association is not restricted only to carriers of HLA-B*27 but also found in HLA-B*40:01 carriers independently of HLA-B*27 genotype

TGFβ receptor gene variants in systemic sclerosis-related pulmonary arterial hypertension: results from a multicentre EUSTAR study of European Caucasian patients

Introduction: Systemic sclerosis (SSc)-related pulmonary arterial hypertension (PAH) has emerged as a major mortality prognostic factor. Mutations of transforming growth factor beta (TGFβ) receptor genes strongly contribute to idiopathic and familial PAH. Objective: To explore the genetic bases of SSc–PAH, we combined direct sequencing and genotyping of candidate genes encoding TGFβ receptor family members. Materials and methods: TGFβ receptor genes, BMPR2, ALK1, TGFR2 and ENG, were sequenced in 10 SSc–PAH patients, nine SSc and seven controls. In addition, 22 single-nucleotide polymorphisms (SNP) of these four candidate genes were tested for association in a first set of 824 French Caucasian SSc patients (including 54 SSc–PAH) and 939 controls. The replication set consisted of 1516 European SSc (including 219 SSc–PAH) and 3129 controls from the European League Against Rheumatism Scleroderma Trials and Research group network. Results: No mutation was identified by direct sequencing. However, two repertoried SNP, ENG rs35400405 and ALK1 rs2277382, were found in SSc–PAH patients only. The genotyping of 22 SNP including the latter showed that only rs2277382 was associated with SSc–PAH (p=0.0066, OR 2.13, 95% CI 1.24 to 3.65). Nevertheless, this was not replicated with the following result in combined analysis: p=0.123, OR 0.79, 95% CI 0.59 to 1.07. Conclusions: This study demonstrates the lack of association between these TGFβ receptor gene polymorphisms and SSc–PAH using both sequencing and genotyping methods

Nouvelles voies de régulation des localisations intra- et extra-cellulaires de la protéine FADD

La protéine FADD (Fas associated death domain) est l adaptateur clé de la voie de signalisation apoptotique dépendante des récepteurs de mort de la famille du TNF (tumor necrosis factor). Au cours des dix dernières années, il est apparu évident qu au-delà de son rôle majeur dans la mort cellulaire, FADD est impliqué dans d autres processus biologiques comme le développement embryonnaire, la réponse immunitaire innée ou encore la progression du cycle cellulaire. De même, il est devenu clair que la localisation subcellulaire de FADD est déterminante pour sa fonction. Identifier les voies de régulation de l expression de la protéine est donc d une importance capitale. En 2008, notre équipe a mis en évidence, dans un modèle murin de la thyro de, un nouveau mécanisme de régulation de l expression de la protéine via la sécrétion. En parallèle, le laboratoire a rapporté que la présence de FADD dans le sérum de patients cancéreux était corrélée à l agressivité des tumeurs et l inflammation. (Tourneur et al, 2012). L objectif de ce travail de thèse était de comprendre le mécanisme par lequel FADD était sécrété, et de déterminer, le cas échéant, les modalités de sa régulation. Un troisième objectif est apparu au cours de la thèse : identifier de nouveaux modes de régulation de l expression de FADD. Au moyen d une lignée modèle humaine, nous avons montré que l expression de la protéine humaine pouvait être régulée via une voie non-conventionnelle de sécrétion, tout comme dans le modèle murin. En parallèle de la caractérisation de cette sécrétion, nous avons montré que celle-ci pouvait être régulée par la kinase anti-apoptotique CK2 (casein kinase 2). Enfin, nous montrons que la CK2 régule la localisation nucléaire de FADD via une phosphorylation dépendante de la sous-unité régulatrice de la kinase et que la CK2 pourrait interagir directement avec FADD. Ces résultats constituent la première démonstration de la régulation de FADD par sécrétion par des cellules humaines et les premiers à rapporter un nouveau mode de régulation de la localisation subcellulaire de FADD par la CK2. Les conséquences de ces résultats en regard des fonctions connus de FADD sont discutéesThe FADD protein (Fas associated death domain) is the key adaptor molecule of the apoptotic signaling pathway triggered by death receptors of the TNF (Tumor necrosis factor) superfamily. During the last decade, it became obvious that, in addition to its major role in cell death, the protein was also involved in other biological processes like the embryonic development, the immune response or even cell cycle progression. Evidence also showed that the protein sub-cellular localization was a key determinant to its functions. Therefore, the identification of underlying regulatory mechanisms dictating FADD expression was of significant importance. In 2008 our laboratory identified, in a thyroid murine model, a new mechanism controlling FADD expression, namely via secretion. We discovered that the loss of FADD expression from tumor cells, by secretion, could be correlated to cancer aggressiveness as well as inflammation (Tourneur 2012). The goal of this thesis work was to apprehend the mechanism by which FADD was secreted and determine, in that case, the modalities of this regulation. A third objective of this work was to identify new potential regulatory pathways of FADD expression. By means of a human cell line model, we showed that, similarly to the mouse model, the expression of human FADD could be regulated via unconventional secretion. In parallel to the characterization of the secretory process itself, we demonstrated that secretion could be negatively regulated by the anti-apoptotic kinase CK2 (casein kinase 2). Finally, we showed that CK2 could regulate FADD nuclear localization via a regulatory sub-unit-dependent phosphorylation and that FADD and CK2 could directly interact. These results are the first to demonstrate that human FADD expression could be regulated via secretion and that FADD sub-cellular localization could be modulated by CK2. The consequences of such regulation with regards to known FADD functions are discussedPARIS5-Bibliotheque electronique (751069902) / SudocSudocFranceF

La clusterine (un nouveau régulateur de la voie NF- B et de la mort cellulaire)

La clusterine: un nouveau régulateur de la voie NF- B et de la mort cellulaire Plusieurs fonctions physiologiques ont été attribuées à la clusterine (CLU), dont le rôle important au cours de l'inflammation et de la tumorogenèse. Nous avons montré que CLU interagit avec I b-a phosphorylé et diminue la translocation de p50/p65. Nous avons aussi généré un ensemble de constructions " flaggées " pour les différentes isoformes de CLU. Les résultats de cette étude montrent que la régulation de la voie NF- B pourrait être restreinte à des séquences particulières de CLU. Nous avons développe une nouvelle approche de ciblage de CLU par la technique d' exon skipping qui permet d'induire préférentiellement la forme nucléaire épissée du gène très mal caractérisée. Nous avons montré que la surexpression de cette forme par cette stratégie induit la mort cellulaire.Clusterin: a new regulator of NF-kappaB pathway and cell death Clusterin is a multifunctional protein that plays numerous roles in mammalian cells. By mean of transcriptomic analysis, we previously demonstrated that lower expression of clu both in tissues and cultured fibroblast-like synoviocytes of rheumatoid arthritis patients compared to osteoarthritic patients. We showed that CLU interacts with phospho-IkB-a and decreases the translocation of p50/p65 to the nucleus. To specify the interaction sites of CLU with its partners and to study the CLU isoforms roles, we generated several molecular constructs coding for various CLU regions of interest and test their role on NF- B pathway and CLU subcellular localization. We have also developed a new approach of "exon skipping" in order to induce preferential expression of the nuclear spliced form of the gene. This strategy will allow a good understanding of nuclear forme poorly characterized.PARIS5-BU Méd.Cochin (751142101) / SudocSudocFranceF